Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, Forecast & News

$42.29
-0.18 (-0.42 %)
(As of 01/24/2020 06:00 AM ET)
Add
Compare
Today's Range
$40.65
Now: $42.29▼
$42.91
50-Day Range
$23.99
MA: $32.47▼
$43.04
52-Week Range
$12.50
Now: $42.29▼
$44.00
Volume1.00 million shs
Average Volume2.59 million shs
Market Capitalization$3.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.68
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLS
Previous Symbol
CUSIPN/A
CIK1492422
Webhttp://www.apellis.com/
Phone502-241-4114

Debt

Debt-to-Equity Ratio1.09
Current Ratio10.12
Quick Ratio10.12

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.86 per share
Price / Book14.79

Profitability

EPS (Most Recent Fiscal Year)($2.34)
Net Income$-127,500,000.00
Net MarginsN/A
Return on Equity-127.91%
Return on Assets-67.08%

Miscellaneous

Employees87
Outstanding Shares74,860,000
Market Cap$3.17 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:APLS Rates by TradingView

(Ad)

Paul Mampilly correctly predicted every bull and bear market over the last two decades. He made millions. His new "Dow 100,000" prediction is his boldest yet. Even more stunning... Paul reveals how you could make millions as it unfolds.

Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals Inc (NASDAQ:APLS) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($1.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.01) by $0.09. View Apellis Pharmaceuticals' Earnings History.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Apellis Pharmaceuticals.

What price target have analysts set for APLS?

10 brokerages have issued 1 year target prices for Apellis Pharmaceuticals' stock. Their forecasts range from $23.00 to $80.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $46.09 in the next year. This suggests a possible upside of 9.0% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.

What is the consensus analysts' recommendation for Apellis Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.

What are Wall Street analysts saying about Apellis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (12/24/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are reiterating our OW rating on Apellis and lowering our 12-month price target to $52 from $57. This morning, Apellis issued a press release highlighting financial and corporate updates for the period ended on 3/31. Our decrease in price target is based off an increased share count, due to the recent March 2019 financing, and an increase to R&D and SG&A projections. With Phase 3 PEGASUS (PNH) enrollment expected to complete by the end of 2Q19, we believe APLS shares represent a strong buying opportunity, ahead of a potential 4Q19 data readout. Below we revisit our thoughts on APL-2 and its potential to be a disruptive addition to the PNH market." (5/8/2019)

Has Apellis Pharmaceuticals been receiving favorable news coverage?

Press coverage about APLS stock has been trending very positive on Friday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 3.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Apellis Pharmaceuticals.

Who are some of Apellis Pharmaceuticals' key competitors?

What other stocks do shareholders of Apellis Pharmaceuticals own?

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the folowing people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 47)
  • Dr. Pascal Deschatelets, Co-Founder & COO (Age 49)
  • Mr. Timothy E. Sullivan, Chief Financial Officer (Age 48)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Medical Affairs (Age 45)
  • Mr. Ahmad Sadr, VP of Technical Operations

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.11%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Lukas Scheibler, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan. View Institutional Ownership Trends for Apellis Pharmaceuticals.

Which major investors are buying Apellis Pharmaceuticals stock?

APLS stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Lukas Scheibler, Morningside Venture Investment and Timothy Eugene Sullivan. View Insider Buying and Selling for Apellis Pharmaceuticals.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $42.29.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $3.17 billion. The company earns $-127,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.View Additional Information About Apellis Pharmaceuticals.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is http://www.apellis.com/.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]


MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  336
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: How do candlesticks reflect price movement?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel